Company intelligence / Profile preview
Treovir Inc.
Bala Cynwyd, PA, UStreovir.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset G207 showed improved survival without serious side effects in peds HGG/GMB phase I study; now enrolling pivotal phase II trial aiming at first approval ever for peds HGG/GMB treatment.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusesOncolytic immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Matica Bio CDMO partnershipAcademic collaborations UAB/Children's AL
Beyond the preview
Go deeper on Treovir Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Treovir Inc..